| LP212194-7 | Methotrexate diglutamate | COMPONENT | 1 |
| LP212195-4 | Methotrexate triglutamate | COMPONENT | 1 |
| LP212196-2 | Methotrexate tetraglutamate | COMPONENT | 1 |
| LP212197-0 | Methotrexate pentaglutamate | COMPONENT | 1 |
| LP212198-8 | Submitter's laboratory test method | COMPONENT | 1 |
| LP212201-0 | Glucose meter to reference method correlation | COMPONENT | 1 |
| LP212202-8 | Methotrexate polyglutamates 1-5 and total panel | COMPONENT | 1 |
| LP212203-6 | Hazelnut (Corylus avellana) recombinant (rCor a) 14 | COMPONENT | |
| LP212204-4 | Dermatophagoides pteronyssinus native (nDer p) 2 | COMPONENT | |
| LP212206-9 | Apple recombinant (rMal d) 3 | COMPONENT | |
| LP212207-7 | English walnut recombinant (rJug r) 3 | COMPONENT | |
| LP212208-5 | English walnut recombinant (rJug r) 1 | COMPONENT | |
| LP212209-3 | Microsatellite instability markers assessed | COMPONENT | 1 |
| LP212210-1 | Microsatellite instability marker BAT25 | COMPONENT | 1 |
| LP212211-9 | Microsatellite instability marker BAT26 | COMPONENT | 1 |
| LP212212-7 | Microsatellite instability marker NR21 | COMPONENT | 1 |
| LP212213-5 | Microsatellite instability marker NR24 | COMPONENT | 1 |
| LP212214-3 | Microsatellite instability marker MONO27 | COMPONENT | 1 |
| LP212215-0 | Microsatellite instability marker D2S123 | COMPONENT | 1 |
| LP212216-8 | Microsatellite instability marker D5S346 | COMPONENT | 1 |
| LP212217-6 | Microsatellite instability marker D17S250 | COMPONENT | 1 |
| LP212218-4 | Phosphatase and tensin homolog (PTEN) protein | COMPONENT | |
| LP212219-2 | Dissection technique | COMPONENT | 1 |
| LP212220-0 | Microsatellite markers exhibiting instability | COMPONENT | 1 |
| LP212221-8 | Microsatellite instability markers assessed | DIVISORS | |
| LP212222-6 | Microsatellite instability marker panel | COMPONENT | 1 |
| LP212223-4 | Cytokines panel | COMPONENT | 1 |
| LP212224-2 | BRAF protein | COMPONENT | |
| LP212225-9 | HIV 2 RNA panel | COMPONENT | 1 |
| LP212252-3 | Progress note - recommended C-CDA R2.0 and R2.1 sections | COMPONENT | 1 |
| LP212254-9 | Procedure note - recommended C-CDA R2.0 and R2.1 sections | COMPONENT | 1 |
| LP212255-6 | Referral note - recommended C-CDA R2.0 and R2.1 sections | COMPONENT | 1 |
| LP212257-2 | Discharge summary - recommended C-CDA R2.1 sections | COMPONENT | 1 |
| LP212258-0 | Discharge summary - recommended C-CDA R2.0 sections | COMPONENT | 1 |
| LP212259-8 | Transfer summary note - recommended C-CDA R2.0 sections | COMPONENT | 1 |
| LP212260-6 | Diagnostic imaging report - recommended C-CDA R2.0 and R2.1 sections | COMPONENT | 1 |
| LP212262-2 | Consultation note - recommended C-CDA R2.0 and R2.1 sections | COMPONENT | 1 |
| LP212263-0 | Continuity of Care Document - recommended C-CDA R2.0 and R2.1 sections | COMPONENT | 1 |
| LP212264-8 | Care plan - recommended C-CDA R2.0 and R2.1 sections | COMPONENT | 1 |
| LP212265-5 | Lower extremity vessel - left | SYSTEM | 1 |
| LP212266-3 | Lower extremity vessel - right | SYSTEM | 1 |
| LP212267-1 | Left pulmonary artery | SYSTEM | 8 |
| LP212268-9 | Right pulmonary artery | SYSTEM | 8 |
| LP212269-7 | Blood banking and transfusion medicine | METHOD | 8 |
| LP212270-5 | Desflurane target | COMPONENT | |
| LP212271-3 | Views for endocrine tumor | COMPONENT | |
| LP212272-1 | W contrast retrograde | CHALLENGE | |
| LP212276-2 | Pelvis | SYSTEM | |
| LP212277-0 | Breast - left | SYSTEM | |
| LP212278-8 | Breast - right | SYSTEM | |